Inagi Reiko, Izuhara Yuko, Tominaga Naoto, Nangaku Masaomi, Kurokawa Kiyoshi, Miyata Toshio
Institute of Medical Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Nephrol Dial Transplant. 2007 Nov;22(11):3311-7. doi: 10.1093/ndt/gfm391. Epub 2007 Jun 25.
We previously identified a novel serine protease inhibitor (serpin), megsin, which is predominantly expressed in the kidney. Megsin expression is up-regulated in human and experimental renal diseases associated with mesangial proliferation and expansion, suggesting that urinary megsin may be a novel diagnostic marker for some renal diseases.
We established a specific and sensitive sandwich enzyme-linked immunosorbent assay (ELISA) for megsin and measured urinary megsin of patients with various renal diseases.
Megsin ELISA specifically detected megsin but not other serpins. The detection limit was 0.04 ng/ml, which allowed detection of urinary megsin in 3.6% of healthy individuals. The antigenic epitope in the urine detected by the ELISA was confirmed as megsin protein by time-of-flight mass spectrometry. Among patients with rapidly progressive glomerulonephritis (n = 18), 55.6% were urinary megsin-positive, while 24.1% in IgA nephropathy (n = 112) and 15.1% in chronic non-IgA glomerulonephritis (n = 245) were urinary megsin-positive, respectively. Among patients with chronic renal failure due to unknown causes (n = 74), 18.9% were positive for urinary megsin. In diabetic patients with or without nephropathy (n = 1073), 12.3% were urinary megsin-positive, while positivity of urinary megsin in patients with non-renal diseases (n = 768) was equivalent (3.3%) to that of healthy individuals. Of note, when urinary megsin-positive patients with diabetic nephropathy (n = 71) were classified into four stages by their proteinuria and estimated glomerular filtration rate, urinary megsin excretion increased as the stage progressed up to stage 3A, suggesting correlation of that with mesangial expansion level. Urinary megsin decreased in the advanced stage, probably reflecting development of glomerulosclerosis.
We established a high-sensitive megsin ELISA, which detects urinary megsin in some patients with renal diseases and in only a few healthy subjects. Megsin ELISA may be a novel diagnostic tool for renal diseases.
我们之前鉴定出一种新型丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制剂), megsin,其主要在肾脏中表达。在与系膜增殖和扩张相关的人类和实验性肾脏疾病中,megsin表达上调,这表明尿megsin可能是某些肾脏疾病的新型诊断标志物。
我们建立了一种针对megsin的特异性和敏感性夹心酶联免疫吸附测定(ELISA),并测量了各种肾脏疾病患者的尿megsin。
Megsin ELISA特异性检测到megsin,但未检测到其他丝氨酸蛋白酶抑制剂。检测限为0.04 ng/ml,这使得能够在3.6%的健康个体中检测到尿megsin。通过飞行时间质谱法确认ELISA检测到的尿液中的抗原表位为megsin蛋白。在快速进展性肾小球肾炎患者(n = 18)中,55.6%的患者尿megsin呈阳性,而在IgA肾病患者(n = 112)中为24.1%,在慢性非IgA肾小球肾炎患者(n = 245)中为15.1%。在病因不明的慢性肾衰竭患者(n = 74)中,18.9%的患者尿megsin呈阳性。在有或无肾病的糖尿病患者(n = 1073)中,12.3%的患者尿megsin呈阳性,而在非肾脏疾病患者(n = 768)中尿megsin的阳性率(3.3%)与健康个体相当。值得注意的是,当将糖尿病肾病尿megsin阳性患者(n = 71)根据蛋白尿和估计的肾小球滤过率分为四个阶段时,尿megsin排泄量随着阶段进展至3A期而增加,这表明其与系膜扩张水平相关。在晚期尿megsin降低,这可能反映了肾小球硬化的发展。
我们建立了一种高灵敏度的megsin ELISA,其可在一些肾脏疾病患者中检测到尿megsin,而在少数健康受试者中未检测到。Megsin ELISA可能是一种用于肾脏疾病的新型诊断工具。